Fulcrum Therapeutics (FULC) Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Accumulated Expenses for 9 consecutive years, with $4.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Accumulated Expenses fell 11.86% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (down 11.86% YoY), while the FY2025 annual figure was $9.1 million, up 17.65% from the prior year.
• Accumulated Expenses fell to $4.4 million in Q2 2026 per FULC's latest filing, from $5.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.5 million in Q2 2022 and bottomed at $4.4 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $7.3 million across 5 years, with a median of $7.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 63.16% — and 2023, when it sank 36.85%.
• Fulcrum Therapeutics' Accumulated Expenses stood at $9.6 million in 2022, then retreated by 8.64% to $8.7 million in 2023, then fell by 11.83% to $7.7 million in 2024, then gained by 17.65% to $9.1 million in 2025, then slumped by 51.89% to $4.4 million in 2026.
• Business Quant data shows FULC's Accumulated Expenses at $4.4 million in Q2 2026, $5.0 million in Q1 2026, and $9.1 million in Q4 2025.